TJPC's subsidiary compound potassium hydrogen phosphate injection has passed the consistency evaluation of generic drugs
TJPC's subsidiary, Tianjin Jiayao Heping Pharmaceutical Co., Ltd., recently received approval from the National Medical Products Administration for the consistency evaluation of potassium hydrogen phosphate injection as a generic drug. This injection is mainly used to correct hypophosphatemia and for parenteral nutrition. Jiayao Heping submitted a supplementary application for consistency evaluation in July 2024, with a total R&D investment of approximately 9.21 million yuan
According to the Zhitong Finance APP, TJPC (600488.SH) announced that its subsidiary Tianjin Jiayao Heping Pharmaceutical Co., Ltd. (referred to as "Jiayao Heping") has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration for the compound potassium hydrogen phosphate injection, which approves the product to pass the consistency evaluation of generic drug quality and efficacy.
As a phosphorus supplement, the compound potassium hydrogen phosphate injection is mainly used for: (1) correcting hypophosphatemia in adult and pediatric patients when oral or enteral nutrition cannot be performed, is insufficient, or is contraindicated; (2) providing parenteral nutrition for adult and pediatric patients when oral or enteral nutrition cannot be performed, is insufficient, or is contraindicated. In July 2024, Jiayao Heping submitted a supplementary application for the consistency evaluation of the compound potassium hydrogen phosphate injection to the Drug Evaluation Center of the National Medical Products Administration, which has been accepted. So far, Jiayao Heping has invested approximately 9.21 million yuan in research and development for the compound potassium hydrogen phosphate injection project
